1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Tyme Ticks On With Mid-Stage Development Of A Broad Cancer Therapy

 
• By Jessica Merrill

The small biotech presented positive interim data from a Phase II trial testing its lead candidate SM-88 in prostate cancer at ESMO and is gearing up to initiate a trial in pancreatice cancer.

Scientist conducting a laboratory experiment in a cancer research facility in the United States, 1951.

Tyme Technologies, Inc. has been working on cancer drug development under the radar, but positive early data on its sole clinical-stage drug – a cancer therapy called SM-88 – has encouraged management to move ahead more aggressively into larger mid-stage clinical testing.

The New York City-based biotech presented positive interim data from a Phase II clinical trial in prostate cancer patients at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.